WAVE Life Sciences (NASDAQ:WVE) was upgraded by equities research analysts at BidaskClub from a “buy” rating to a “strong-buy” rating in a research report issued on Saturday.

Other research analysts have also issued research reports about the company. Mizuho set a $34.00 price objective on WAVE Life Sciences and gave the stock a “buy” rating in a report on Friday, August 18th. Jefferies Group reissued a “buy” rating and set a $40.00 price objective (down previously from $42.00) on shares of WAVE Life Sciences in a report on Thursday, August 10th. Zacks Investment Research raised WAVE Life Sciences from a “sell” rating to a “hold” rating in a report on Thursday, October 12th. Finally, Leerink Swann reissued an “outperform” rating and set a $53.00 price objective (up previously from $42.00) on shares of WAVE Life Sciences in a report on Wednesday, November 15th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. WAVE Life Sciences presently has an average rating of “Buy” and an average target price of $41.60.

Shares of WAVE Life Sciences (NASDAQ WVE) traded up $2.15 during midday trading on Friday, hitting $39.35. The stock had a trading volume of 437,935 shares, compared to its average volume of 222,025. WAVE Life Sciences has a 52 week low of $15.15 and a 52 week high of $39.50. The company has a quick ratio of 11.50, a current ratio of 11.50 and a debt-to-equity ratio of 0.01.

WAVE Life Sciences (NASDAQ:WVE) last issued its quarterly earnings data on Thursday, November 9th. The company reported ($0.94) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.97) by $0.03. WAVE Life Sciences had a negative return on equity of 59.52% and a negative net margin of 3,338.68%. The company had revenue of $0.68 million during the quarter, compared to analyst estimates of $0.77 million. sell-side analysts anticipate that WAVE Life Sciences will post -3.76 EPS for the current year.

In other news, Director Ra Capital Management, Llc bought 423,398 shares of the company’s stock in a transaction that occurred on Tuesday, November 14th. The stock was bought at an average price of $23.34 per share, for a total transaction of $9,882,109.32. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Chandra Vargeese sold 1,500 shares of the business’s stock in a transaction that occurred on Wednesday, November 22nd. The stock was sold at an average price of $35.00, for a total value of $52,500.00. The disclosure for this sale can be found here. Insiders own 53.00% of the company’s stock.

Large investors have recently added to or reduced their stakes in the stock. American International Group Inc. lifted its position in WAVE Life Sciences by 7.1% in the 1st quarter. American International Group Inc. now owns 4,554 shares of the company’s stock worth $125,000 after buying an additional 302 shares during the last quarter. Nationwide Fund Advisors lifted its position in WAVE Life Sciences by 58.1% in the 2nd quarter. Nationwide Fund Advisors now owns 6,720 shares of the company’s stock worth $125,000 after buying an additional 2,470 shares during the last quarter. Wells Fargo & Company MN bought a new stake in WAVE Life Sciences in the 3rd quarter worth approximately $136,000. The Manufacturers Life Insurance Company lifted its position in WAVE Life Sciences by 71.0% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 9,422 shares of the company’s stock worth $175,000 after buying an additional 3,912 shares during the last quarter. Finally, Strs Ohio bought a new stake in WAVE Life Sciences in the 3rd quarter worth approximately $194,000. Institutional investors own 73.74% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This piece of content was first posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another domain, it was illegally stolen and reposted in violation of international copyright and trademark laws. The original version of this piece of content can be read at https://www.americanbankingnews.com/2017/12/02/bidaskclub-upgrades-wave-life-sciences-wve-to-strong-buy.html.

WAVE Life Sciences Company Profile

WAVE Life Sciences Ltd. is a genetic medicines company. The Company, through its synthetic chemistry drug development platform, designs, develops and commercializes a pipeline of nucleic acid therapeutic candidates for genetically defined diseases. The Company is engaged in developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins.

Analyst Recommendations for WAVE Life Sciences (NASDAQ:WVE)

Receive News & Ratings for WAVE Life Sciences Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for WAVE Life Sciences Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.